Full Year Guidance
Organon does not provide GAAP financial measures on a forward-looking basis because the company cannot predict with reasonable certainty and without unreasonable effort, the ultimate outcome of legal proceedings, unusual gains and losses, the occurrence of matters creating GAAP tax impacts, and acquisition-related expenses. These items are uncertain, depend on various factors, and could be material to Organon's results computed in accordance with GAAP.
Full year 2024 actual results and 2025 financial guidance are presented below on a non-GAAP basis, except revenue.
| Full Year 2024 Actuals | Full Year 2025 Guidance | |
| Revenue | $6.403B | $6.125B-$6.325B |
| FX translation headwind | ~$80M | ~$200M |
| Adjusted gross margin | 61.6% | 60.0%-61.0% |
| SG&A | $1.57B/25% | Mid-20% range |
| R&D | $440M/6.9% | Upper single-digit |
| IPR&D* | $81M | - |
| Adjusted EBITDA margin (Non-GAAP) | 30.6% | 31.0%-32.0% |
| Interest | $520M | ~$510M |
| Depreciation | $126M | ~$135M |
| Effective non-GAAP tax rate | 18.8% | 22.5%-24.5% |
| Fully diluted weighted average shares outstanding | 259M | ~263M |
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。